Drugs / NNC0165-1875
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03707990 | Oct 2018 → Aug 2019 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04969939 | Jul 2021 → Dec 2022 | obesity disorder | Novo Nordisk A/S | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0165-1875 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03707990 ↗ |
| Route | Subcutaneous | “Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection.” NCT03707990 ↗ |